Premium
Flow Cytometric Study of Site‐Directed Chemotherapy with Estradiol‐17β as a Drug Carrier to Human Endometrial Adenocarcinoma Cells in vitro
Author(s) -
Nishiya Iwao,
Yoshizumi Noboru,
Sato Masayuki,
Kagabu Teruo,
Fujiwara Jun,
Yoshizaki Akira
Publication year - 1987
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1987.tb00278.x
Subject(s) - flow cytometry , chemistry , methotrexate , population , paclitaxel , in vitro , cell cycle , sodium butyrate , medicine , endocrinology , cell , chemotherapy , biology , microbiology and biotechnology , biochemistry , environmental health , gene
The effects of Estracyt®, HN 2 (nitrogen mustard) derivative of estradiol‐17β, and free HN 2 on the cell kinetics of the estrogen receptor (ER) positive human endometrial cancer cell line HEC‐1, were investigated using flow cytometry. HN 2 at 1 μg/ml showed a marked increase in the S phase and a decrease in the G 0 + G i phase. However, with equivalent doses of Estracyt® at 10 μg/ml, the accumulation in the G 2 + M phase was even more marked. Synchronization in the S phase with methotrexate (MTX) showed no increase in sensitivity to these drugs. The above results suggest that the free HN 2 has an effect regardless of the cell cycle phase, whereas the effects of Estracyt® may depend on a fixed population of target cells existing in the G 0 +G 1 , S and G 2 + M phases. Synchronization in the G 1 phase with sodium n ‐butyrate could increase the target effects of Estracyt® in the S phase.